Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

PHASE2CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Actinic Keratosis
Interventions
DRUG

Broad Area ALA 1-hour incubation

20% ALA, broad area, 1 hour incubation

DRUG

Broad Area ALA 2 hour incubation

20% ALA broad area 2-hour incubation

DRUG

broad area ALA 3-hour incubation

20% ALA broad area 3 hour incubation

DRUG

Spot ALA 2 hour incubation

20% ALA spot 2 hour incubation

DRUG

Vehicle PDT

Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.

DEVICE

Blue Light Treatment

10 J/cm2 blue light delivered at 10 mW/cm2

Trial Locations (13)

23507

Virginia Clinical Research Inc, Norfolk

37215

Tennessee Clinical Research Center, Nashville

45220

Dermatology Research Center of Cincinnati, Cincinnati

46168

The Indiana Clinical Trials Center, PC, Plainfield

55432

Minnesota Clinical Study Center, Fridley

60005

Altman Dermatology Associates, Arlington Heights

77056

Suzanne Bruce and Associates, P.A.,The Center for Skin Research, Houston

78759

DermResearch, Inc., Austin

83704

Northwest Clinical Trials, Inc., Boise

90045

Dermatology Research Associates, Los Angeles

92037

UCSD Dermatology Perlman Ambulatory Clinic, La Jolla

92123

Therapeutics Clinical Research, San Diego

97223

Oregon Medical Research Center, PC, Portland

Sponsors
All Listed Sponsors
lead

DUSA Pharmaceuticals, Inc.

INDUSTRY